uniQure N.V. (QURE): H.C. Wainwright Names the Stock as Top Pick for 2025 with 365% Upside Potential!
Reading Time: 4 minutes
uniQure N.V. (QURE) is a leading biotechnology company specializing in the development of gene therapies for rare genetic disorders. The company, headquartered in the Netherlands, is known for its expertise in AAV gene therapy (adeno-associated viral vectors) and its innovative product portfolio targeting diseases that currently have limited treatment options. uniQure's core technology platform has allowed the development of several therapies that are in both clinical trials and early commercialization. Notable products include Hemgenix, a gene...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
